HALO Halozyme Therapeutics PE ratio, current and historical analysis

As of Apr 24, 2025, the HALO stock has a P/E ratio of 16.93. The calculation is based on the latest EPS of $3.5 and the stock price of $59.25 per share. The PE ratio currently is comparable to its last 4-quarter average.

HALO PE ratio history

How has HALO's PE ratio performed in the past

The mean historical PE ratio of Halozyme Therapeutics over the last eight years is 31.45. The current 16.93 price-to-earnings ratio is 46% less than the historical average. Analyzing the last eight years, HALO's PE ratio reached its highest point in the Sep 2020 quarter at 146, with a price of $26.28 and an EPS of $0.18. The Mar 2022 quarter saw the lowest point at 12.95, with a price of $39.88 and an EPS of $3.08.

Today
17.28
Average
31.45
Median
23.37
Minimum
12.95
Maximum
146

Halozyme Therapeutics PE ratio by year

Maximum annual increase: 173.47% in 2022

Maximum annual decrease: -68.73% in 2021

Year PE ratio PE change Price EPS
2024 13.66 -21.27% $47.81 $3.5
2023 17.35 -54.88% $36.96 $2.13
2022 38.45 173.47% $56.9 $1.48
2021 14.06 -68.73% $40.21 $2.86
2020 44.96 N/A $42.71 $0.95
2019 N/A N/A $17.73 -$0.5
2018 N/A N/A $14.63 -$0.56
2017 44.04 N/A $20.26 $0.46
2016 N/A N/A $9.88 -$0.81
2015 N/A N/A $17.33 -$0.25
2014 N/A N/A $9.65 -$0.56
2013 N/A N/A $14.99 -$0.74
2012 N/A N/A $6.71 -$0.48
2011 N/A N/A $9.51 -$0.19
2010 N/A N/A $7.92 -$0.56

Halozyme Therapeutics PE ratio by quarter (TTM)

Year PE ratio PE change Price EPS
Dec 2024 13.66 -26.72% $47.81 $3.5
Sep 2024 18.64 -7.08% $57.24 $3.07
Jun 2024 20.06 20.84% $52.36 $2.61
Mar 2024 16.6 -4.32% $40.68 $2.45
Dec 2023 17.35 -13.25% $36.96 $2.13
Sep 2023 20 -3.52% $38.2 $1.91
Jun 2023 20.73 -27.8% $36.07 $1.74
Mar 2023 28.71 -25.33% $38.19 $1.33
Dec 2022 38.45 47.83% $56.9 $1.48
Sep 2022 26.01 53.72% $39.54 $1.52
Jun 2022 16.92 30.66% $44 $2.6
Mar 2022 12.95 -7.89% $39.88 $3.08
Dec 2021 14.06 0.57% $40.21 $2.86
Sep 2021 13.98 -49.2% $40.68 $2.91
Jun 2021 27.52 -20.78% $45.41 $1.65

HALO average PE ratio chart

What is the average PE ratio of HALO for the past years

The current PE ratio of HALO is under its 3, 5 and 10-year averages.

3-year avg
21.56
5-year avg
29.52
10-year avg
31.45
15-year avg
31.45

HALO PE vs peers

What is HALO's PE ratio compared to its peers

HALO's PE ratio is less than its peer stocks LLY and JNJ, but it is above PFE's. Halozyme Therapeutics's current PE ratio of 16.93 is less than the average of its peers, which is 38.24.

Stock name PE ratio Market cap
PFE Pfizer Inc 16.14 $129.9B
JNJ Johnson & Johnson 17.06 $371.93B
HALO Halozyme Therapeutics Inc 17.28 $7.45B
MNKD Mannkind Corp 47.4 $1.44B
LLY ELI LILLY & Co 75.22 $838.69B
BAX Baxter International Inc N/A $15.46B

Frequently asked questions

What is Halozyme Therapeutics's PE ratio?

As of Apr 24, 2025, HALO stock has a price to earnings ratio of 16.93.

What is the 3-year average PE ratio for Halozyme Therapeutics (HALO)?

Over the last 3 years, the average PE ratio for HALO stock is 21.56.

What is the 5-year average PE ratio for Halozyme Therapeutics (HALO)?

Over the last 5 years, the average PE ratio for HALO stock is 29.52.

What is the highest PE ratio for HALO?

Over the last eight years, the quarterly PE ratio reached its highest level at 146 in the Sep 2020 quarter.

How does the current PE ratio for HALO compare to its historical average?

HALO's current price to earnings ratio is 46% below its 8-year historical average.

How is HALO's PE ratio calculated (Halozyme Therapeutics PE ratio formula)?

To determine the P/E ratio, divide the latest stock price by the TTM earnings per share (EPS). As of today (Apr 24, 2025), Halozyme Therapeutics's share price is $59.25. The company's earnings per share for the trailing twelve months (TTM) ending Dec 2024 is $3.5. Therefore, Halozyme Therapeutics's price to earnings ratio for today is 16.93. PE RATIO(16.93) = STOCK PRICE($59.25) / TTM EPS($3.5)

All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.